The All-Party Parliamentary Group on Pancreatic Cancer has today welcomed news that Cancer Research UK will be investing £10m into a pancreatic cancer research project.
The funding will go to PRECISION Panc led by Professor Andrew Biankin at the University of Glasgow. This will be the largest ever single investment into the disease. The project aims to match patients to the right clinical trials for their particular tumour type, ensuring that they receive the most effective treatment for them. It is hoped that this personalised approach will result in more patients living longer with the disease, which currently has the lowest survival rate of the 21 most common cancers.
Just 5% of pancreatic cancer patients live for five years or more after diagnosis, a statistic that has hardly improved in 40 years. Without more research investment the disease is set to become the fourth biggest cancer killer by 2026.
Commenting, APPG Chair Nic Dakin, said: “The announcement of £10m of funding for PRECISION Panc – the biggest single investment into a pancreatic cancer research study – is a huge step forward for this disease which has historically suffered from an appalling lack of research funding. The investment will benefit hundreds of pancreatic cancer patients by helping them gain faster access to the best clinical trials for them.
Currently, there are very few treatments for pancreatic cancer. Research investments, like the one announced by Cancer Research UK today, are vital for ensuring patients have more treatment options now and in the future.”